Filipovic Branka, Marjanovic-Haljilji Marija, Mijac Dragana, Lukic Snezana, Kapor Suncica, Kapor Slobodan, Starcevic Ana, Popovic Dusan, Djokovic Aleksandra
Department of Gastroenterology, Clinical and Hospital Center "Dr Dragisa Misovic-Dedinje", Heroja Milana Tepica 1, 11020 Belgrade, Serbia.
Faculty of Medicine, University of Belgrade, Dr Subotica Starijeg 8, 11000 Belgrade, Serbia.
Curr Issues Mol Biol. 2023 Nov 15;45(11):9132-9148. doi: 10.3390/cimb45110573.
Metabolic-associated liver disease (MAFLD) affects up to 70% of overweight and more than 90% of morbidly obese people, and its pathogenesis is rather complex and multifactorial. The criteria for MAFLD include the presence of hepatic steatosis in addition to one of the following three criteria: overweight or obesity, presence of type 2 diabetes mellitus (T2DM), or evidence of metabolic dysregulation. If the specific criteria are present, the diagnosis of MAFLD can be made regardless of alcohol consumption and previous liver disease. The pathophysiological mechanisms of MAFLD, including inflammation, lipotoxicity, mitochondrial disfunction, and oxidative stress, as well as the impact of intestinal gut microbiota, are constantly being elucidated. Treatment strategies that are continually emerging are based on different key points in MAFLD pathogenesis. Yet, the ideal therapeutic option has still not been found and future research is of great importance, as MAFLD represents a multisystemic disease with numerous complications.
代谢相关脂肪性肝病（MAFLD）影响高达70%的超重人群以及超过90%的病态肥胖人群，其发病机制相当复杂且具有多因素性。MAFLD的诊断标准包括肝脂肪变性，以及以下三项标准中的一项：超重或肥胖、2型糖尿病（T2DM）、或代谢失调的证据。如果存在特定标准，无论饮酒情况和既往肝病如何，均可诊断为MAFLD。MAFLD的病理生理机制，包括炎症、脂毒性、线粒体功能障碍和氧化应激，以及肠道微生物群的影响，都在不断被阐明。不断涌现的治疗策略基于MAFLD发病机制中的不同关键点。然而，尚未找到理想的治疗方案，未来的研究至关重要，因为MAFLD是一种具有众多并发症的多系统疾病。
